Tag archive of targets

Iclusig – pro
doc at microscope

Ponatinib (Iclusig, AP24534) was FDA approvedĀ for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trialĀ  and has activity against the T315I mutation, which confers resistant to other CML drugs. It targets the Bcr-Abl tyrosine kinase, as well as VEGFR, PDGFR, FGFR, the SRC kinases,

Read more